Fatal HBV-Related Liver Failure during Lamivudine Therapy in a Patient with Non-Hodgkin's Lymphoma

Marcucci F. , Mele A. , Spada E. , Candido A. , Bianco E. , Pulsoni A. , Chionne P. , Madonna E. , Cotichini R. , Barbui A. , De Renzo A. , Dore F. , Iannitto E. , Liso V. , Martino B. , Montanaro M. , Pagano L. , Musto P. , Rapicetta M. : High prevalence of hepatitis B virus infection in B cell non Hodgkin's lymphoma. Hematologica, 91: 554–557, 2006.

Ozguroglu M. , Bilici A. , Turna H. , Serdengecti S. : Reactivation of hepatitis B virus infection with cytotoxic therapy in non Hodgkin's lymphoma. Med Oncol, 21: 67–72, 2004.

Saif M.W. , Little R.F. , Hamilton J.M. , Allegra C.J. , Wilson W.H. : Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann Oncol, 12: 123–129, 2001.

Li P.C. , Poh S.B. , Lee M.Y. , Hsiao L.T. , Chen P.M. , Chiou T.J. : Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol, 81, 349–351, 2005.

Lok A.S. , McMahon BJ ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD): Chronic hepatitis B: update of recommendations. Hepathology, 39: 857–861, 2004.

Simpson N.D. , Simpson P.W. , Ahmed A.M. , Nguyen M.H. , Garcia G. , Keeffe E.B. , Ahmed A. : Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol, 37: 68–71, 2003.

Li Y.H. , He Y.F. , Jang W.Q. , Wang F.H. , Lin X.B. , Zhang L. , Xia Z.J. , Sun X.F. , Huang H.Q. , Lin T.Y. , He Y.J. , Guan Z.Z. : Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer, 106: 1320–1325, 2006.

Kaway Y. , Ikegaya S. , Hata M. , Kawahito M. , Imamura S. , Yoshida A. , Tsutani H. , Ueda T. : Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. Ann Hematol, 80: 482–484, 2001.

Yeo W. , Chan P.K. , Ho W.M. , Zee B. , Lam K.C. , Lei K.I. , Chan A.T. , Mok T.S. , Lee J.J. , Leung T.W. , Zhong S. , Johnson P.J. : Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol, 22: 927–934, 2004.

Profilassi e terapia dell'epatite B nei pazienti immunocompromessi. Associazione Italiana per lo Studio del Fegato (AISF), Turin, 2005.

Law J.K. , Ali J.A. , Harrigan P.R. , Sherlock C.H. , Savage K.J. , Yoshida E.M. : Fatal post lymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a non cirrhotic patient. Am J Hematol, 81: 969–972, 2006.

Nafa S. , Ahmed S. , Tavan D. , Pichoud C. , Berby F. , Stuyver L. , Johnson M. , Merle P. , Abidi H. , Trépo C. , Zoulim F. : Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology, 32: 1078–1088, 2000.

Picardi M. , Pane F. , Quintarelli C. , De Renzo A. , Del Giudice A. , De Divitiis B. , Persico M. , Ciancia R. , Salvatore F. , Rotoli B. : Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematol, 88: 1296–1303, 2003.

Peters M.G. , Hann Hw H. , Martin P. , Heathcote E.J. , Buggisch P. , Rubin R. , Bourliere M. , Kowdley K. , Trepo C. , Gray Df D. , Sullivan M. , Kleber K. , Ebrahimi R. , Xiong S. , Brosgart C.L. : Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 126: 91–101, 2004.

Yim H.J. , Hussain M. , Liu Y. , Wong S.N. , Fung S.K. , Lok A.S. : Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology, 44: 703–712, 2006.